This website uses cookies to improve the site and your experience. By continuing to browse the site, you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, you can modify your browser settings appropriately, or you may visit our cookies page.
TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is taken orally (in a capsule). TECFIDERA has been shown in research studies to reduce the number of relapses and the development of new brain lesions in people with relapsing forms of MS compared with a placebo (a capsule containing no active ingredient).
It is not known if TECFIDERA will harm an unborn baby, as TECFIDERA has not been studied in pregnant women. Please speak with your doctor if you have any questions about TECFIDERA and pregnancy. The goal of TecGistry, the TECFIDERA Pregnancy Exposure Registry, is to monitor how the use of TECFIDERA might affect women’s pregnancies and their babies. In the future, other pregnant women who are exposed to TECFIDERA may have more information as a result of this registry about how their pregnancies and babies may or may not be affected.
For additional important safety information, please see full Prescribing Information and Patient Information. This is not intended to replace discussions with your doctor.
You will then be contacted by your local Registry Coordinating Center (RCC).
You can also: